Literature DB >> 31129197

Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol.

Mahmoud Khodabandeh1, Ali Rostami2, Katayoun Borhani1, H Ray Gamble3, Mohsen Mohammadi4.   

Abstract

This report describes the first case of visceral leishmaniasis (VL) resistant to pentavalent antimonials and also the first use of combinational therapy in Iran. The patient was a two-year old boy, from a non-endemic area for leishmaniasis in northern Iran, presenting with pentavalent antimonial resistant VL. Additional treatment with conventional and liposomal amphotericin B was not effective. A complete cure was achieved following a three week treatment with liposomal amphotericin B (5 mg/kg/day for 5 days, then on the 14th and 21st days), allopurinol (25 mg/day for 5 days, then on the 14th and 21st days) and interferon gamma (50 μg/m2 subcutaneously three times weekly). Our results suggest a need for further studies to identify resistant Leishmania species and their susceptibility to different treatment regimens.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amphotericin B; Interferon gamma; Iran; Resistant; Visceral leishmaniasis

Mesh:

Substances:

Year:  2019        PMID: 31129197     DOI: 10.1016/j.parint.2019.101934

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  2 in total

1.  Disseminated Leishmaniasis Due to Using Immunosuppression Drugs: A Case Report.

Authors:  Maryam Afshoon; Mohammadreza Abdolsalehi; Golnaz Alinia; Katayoun Borhani; Bahareh Yaghmaie; Mahmoud Khodabandeh
Journal:  Iran J Parasitol       Date:  2020 Apr-Jun       Impact factor: 1.012

Review 2.  Nanoparticles for antiparasitic drug delivery.

Authors:  Yuzhu Sun; Dongmei Chen; Yuanhu Pan; Wei Qu; Haihong Hao; Xu Wang; Zhenli Liu; Shuyu Xie
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.